How we know
Every link on this study, and who decided it
The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.
Why Cisplatin is on this study
- The record lists it as a treatment.
- Claude Opus 5.5 judged it tested: part of what the study tests. Nov 3, 2026, 2:43 AM UTC
- The role rule says the same.
- So Cisplatin's page lists this study under “Testing it”.
- The record changed after this reading. Until it is read again, the page keeps the reading and says so.
Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.
Cisplatin
From the registry record2 judgments on this linkAll judgments on this study
| When | Link | Judge | Decision | State |
|---|---|---|---|---|
| 1 version of the record seen on ClinicalTrials.gov, Nov 17 · changes seen, not judgments | ||||
| Nov 3 | Cisplatin | Claude Opus 5.5 | Tested | Read an older version |
| Nov 3 | Durvalumab | Claude Opus 5.5 | Tested | Replaced |
| Nov 3 | Fluorouracil | Claude Opus 5.5 | Tested | Read an older version |
| Nov 3 | Gemcitabine | Claude Opus 5.5 | Tested | Read an older version |
| Nov 3 | Mitomycin | Claude Opus 5.5 | Tested | Read an older version |
| Nov 17 | The record itself | Rule based · nightly check | Reading set aside | Current |
| Nov 18 | The record itself | Rule based · nightly check | Reading kept | Current |
| Nov 18 | Cisplatin | Rule based · role rule | Tested | Current |
| Nov 18 | Durvalumab | Rule based · role rule | Tested | Current |
| Nov 18 | Fluorouracil | Rule based · role rule | Tested | Current |
| Nov 18 | Gemcitabine | Rule based · role rule | Tested | Current |
| Nov 18 | Mitomycin | Rule based · role rule | Tested | Current |
| Nov 20 | Durvalumab | Claude Opus 5.5 | Tested | Draft |
| Nov 20 | The record itself | Rule based · nightly check | Read again | Current |
| As of now | Urinary Bladder Neoplasms | Rule based · main-condition rule | Main condition | Current |
The rules, in plain words
“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.
Which drugs a study tests
Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.
Where the whole record has been read, that reading's answer replaces the rule's.
What a study is mainly about
Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.
Checked against studies judged one by one; the study page says when it differs from the registry.
When a study changes after it was read
Every night, studies whose record changed are compared with the last reading. A change to sites or dates leaves the reading as it is; a reworded entry keeps it; a change to the treatments or conditions marks it to be read again.
Until it is read again, the page shows the last reading and says so.